About
SBE’s alternative financing instrument enables sustainability for clinical-stage biotechnology companies by offering an insurance policy on the high attrition rate of Phase II drug candidates – the ability to transfer technical risk to the capital markets at the time in a drug candidate’s lifecycle when the greatest amount of uncertainty is traded for the greatest amount of enterprise value.